Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSDBPR108 is an inhibitor of dipeptidyl peptidase 4 (DPP-4; IC50 = 0.015 µM).1 It is selective for DPP-4 over DPP-8 and DPP-9 (IC50s = >50 µM for both). DBPR108 (10 mg/kg) increases plasma levels of glucagon-like peptide 1 (GLP-1) and insulin in rats.2 It reduces blood glucose levels in an oral glucose tolerance test in mice when administered at a dose of 3 mg/kg.1 DBPR108 (0.1 mg/kg), alone and in combination with the biguanide metformin (Item No. 13118), decreases blood glucose levels in an oral glucose tolerance test in a mouse model of high-fat diet-induced obesity.2
WARNING This product is not for human or veterinary use.
1. (2S,4S)-
2. DBPR108, a novel dipeptidyl peptidase-